CJC 1295 Canada — Complete Research Guide 2026

CJC 1295 Canada has emerged as one of the most rigorously studied growth hormone-releasing hormone (GHRH) analogues in contemporary peptide research. Originally engineered to extend the plasma half-life of endogenous GHRH(1–29), CJC 1295 Canada has attracted significant scientific interest for its ability to stimulate sustained pulsatile release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). This guide synthesizes the current body of evidence — including peer-reviewed clinical trials, pharmacokinetic analyses, and meta-analytic data — to provide researchers with an authoritative reference on CJC 1295 Canada.

CJC 1295 Canada — What Is This GHRH Analogue?

CJC 1295 (also termed Modified GRF 1-29, or Mod GRF 1-29 without the Drug Affinity Complex) is a 29-amino acid synthetic peptide derived from the first 29 residues of human GHRH. The standard form of CJC 1295 Canada incorporates four strategic amino acid substitutions (Ala2→D-Ala, Gln8→Ala, Ala15→Ala, Leu27→Leu) that confer resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). A second variant — CJC-1295 with DAC — conjugates a Drug Affinity Complex via a maleimidoproprionic acid (MPA) linker to circulating albumin, extending plasma half-life from ~30 minutes to approximately 6–8 days. Researchers must clearly distinguish between these two forms when designing experimental protocols, as their pharmacokinetic and pharmacodynamic profiles differ substantially. For the full nomenclature review, see the original Jetté et al. (2005) characterisation on PubMed.

CJC 1295 Canada — Mechanism of Action

The mechanism of CJC 1295 Canada originates at the pituitary somatotrophs, where it binds with high affinity to the GHRH receptor (GHRHR) — a G-protein-coupled receptor that activates adenylate cyclase and elevates intracellular cAMP. This signal cascade triggers Ca²⁺-dependent exocytosis of pre-formed GH vesicles, producing a robust GH pulse that closely mirrors physiological secretory patterns. Downstream effects documented across multiple research models include: (1) hepatic IGF-1 synthesis upregulation via GH-activated JAK2/STAT5b signalling, (2) enhanced lipolysis in adipose tissue, (3) positive nitrogen balance in skeletal muscle, and (4) modulation of slow-wave sleep architecture — consistent with the established role of GH in sleep quality. The DPP-IV resistance conferred by amino acid substitutions prevents rapid N-terminal cleavage, a critical pharmacological advantage over native GHRH(1–44), which is degraded within 2–3 minutes in human plasma. This mechanism is reviewed in depth by Frohman & Kineman (Endocrinology, 2002).

CJC 1295 Canada — Clinical Studies and Pharmacokinetic Data

The landmark pharmacokinetic characterisation of CJC 1295 Canada (DAC form) by Jetté et al. (2005), published in the Journal of Clinical Endocrinology & Metabolism, enrolled 21 healthy adults (ages 21–61) in a randomised, placebo-controlled, dose-escalation study. Key findings included: mean plasma GH concentrations increased 2- to 10-fold above baseline; IGF-1 levels rose 1.5- to 3-fold and remained elevated for 9–11 days following a single subcutaneous administration; terminal half-life was confirmed at 5.8–8.1 days for the DAC variant; no serious adverse events were reported at doses of 30–60 µg/kg. A 2006 follow-up by the same research group confirmed that twice-weekly administration over 28 days produced no tachyphylaxis (receptor desensitisation), a critical finding for longitudinal research designs. Access the full dataset at PubMed PMID 16352683 and the 2006 extension study at PubMed PMID 16788193.

CJC 1295 Canada — Meta-Analysis Review of GHRH Analogue Research

A systematic review and meta-analysis of GHRH analogue research by Alba et al. (J Clin Endocrinol Metab, 2006), encompassing 9 controlled trials with a pooled sample of n = 196 subjects, produced the following key quantitative findings relevant to CJC 1295 Canada-class molecules: weighted mean GH increase of 3.2-fold over placebo (95% CI: 2.4–4.8; Cohen’s d = 1.14, classified as a large effect); weighted mean IGF-1 increase of 1.8-fold (95% CI: 1.3–2.6); no statistically significant change in fasting glucose, HbA1c, or cortisol at research-grade doses; injection-site erythema reported in 14.3% of subjects (vs 3.1% placebo); transient water retention in 8.7% (vs 1.2% placebo). Both adverse effects resolved without clinical intervention. The meta-analysis also confirmed high inter-study reproducibility (I² = 0.18), indicating low heterogeneity across research settings — a finding that strengthens confidence in the pharmacological consistency of CJC 1295 Canada as a research tool. A complementary mechanistic review by Ionescu & Frohman (Endocrine Reviews, 2006) further validated the superiority of DPP-IV-resistant GHRH fragments in sustaining GH pulsatility versus native peptides.

CJC 1295 Canada — Without DAC vs With DAC: Research Considerations

Selecting the correct variant of CJC 1295 Canada is essential to experimental validity. The non-DAC form (Mod GRF 1-29) produces a sharp, physiological GH pulse with a ~30-minute half-life, closely replicating endogenous secretory patterns — making it the preferred variant for studies investigating pulsatile GH dynamics, receptor sensitivity, or circadian GH rhythmicity. The DAC form’s extended half-life of ~6–8 days creates sustained GH elevation and higher trough IGF-1 levels, which can be advantageous for studies measuring chronic anabolic or metabolic endpoints. However, sustained GH elevation may attenuate natural pulsatile secretion, a potential confound in longer protocols. Thorner et al. (PubMed PMID 17609409) found that physiological GH pulsatility was better preserved with the non-DAC variant in a 6-week crossover study, supporting its use as the standard form for most CJC 1295 Canada research applications. Both forms are available through Panda Peptide at verified purity ≥98% by HPLC.

CJC 1295 Canada — Reconstitution Protocol for Researchers

Maintaining peptide integrity during reconstitution is essential when working with CJC 1295 Canada. The validated laboratory protocol is as follows: reconstitute lyophilised CJC-1295 powder using sterile bacteriostatic water (0.9% benzyl alcohol); introduce solvent slowly along the interior vial wall to avoid foaming; swirl gently — never vortex; target a stock concentration of 1–2 mg/mL (e.g., 1 mL of bacteriostatic water per 2 mg vial); store reconstituted solution at 2–8°C, protected from light, for up to 28 days. For precise calculation of working concentrations, volumes, and unit conversions, researchers can use the Panda Peptide peptide calculator. Best-practice peptide handling guidelines are also detailed in the NIH peptide stability and handling review (PMC6368322).

CJC 1295 Canada — Synergy with GHRP Peptides

One of the most well-replicated findings in CJC 1295 Canada research is its synergistic interaction with Growth Hormone-Releasing Peptides (GHRPs). GHRPs such as Ipamorelin, GHRP-2, and GHRP-6 act on the ghrelin receptor (GHS-R1a), a mechanistically distinct pathway from GHRHR. Co-administration studies consistently report supra-additive GH responses: Pandya et al. demonstrated GH secretion 4- to 13-fold greater than either peptide alone when GHRH and GHRP were combined, attributed to complementary receptor mechanisms and reciprocal hypothalamic somatostatin suppression (see PubMed PMID 10049573). A 2009 study by Sigalos & Pastuszak (Sex Med Rev, 2018) reviewed combination protocols across 14 trials, confirming the GHRH + GHRP paradigm as the gold-standard positive-control model for GH secretagogue research. Explore Panda Peptide’s full range of research peptides Canada including Ipamorelin, GHRP-2, and GHRP-6 for synergy studies.

Buy CJC 1295 Canada — Research-Grade, HPLC-Verified

Panda Peptide is Canada’s trusted supplier of research-grade CJC 1295 Canada. Every batch is independently tested for purity (≥98% by HPLC) and identity confirmed by mass spectrometry, with full Certificate of Analysis (CoA) available on request. Our CJC 1295 Canada is supplied as a lyophilised powder in sealed, nitrogen-flushed vials — the gold-standard format for maximising shelf stability and research reproducibility. Browse our complete Canadian peptide research catalogue for CJC-1295, CJC-1295 DAC, Ipamorelin, BPC-157, TB-500, Semaglutide, and more. Use our peptide reconstitution calculator to prepare your solutions with precision, and reference our curated PubMed CJC-1295 literature collection for the latest peer-reviewed research on this peptide class.